nach oben

Current Heart Failure Reports

Erschienen in:

22.09.2017 | Pharmacologic Therapy (W H W Tang, Section Editor)

MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential

verfasst von: Palak Shah, Michael R. Bristow, J. David Port

Erschienen in: Current Heart Failure Reports | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Heart failure is increasing in prevalence with a lack of recently developed therapies that produce major beneficial effects on its associated mortality. MicroRNAs are small non-coding RNA molecules that regulate gene expression, are differentially regulated in heart failure, and are found in the circulation serving as a biomarker of heart failure.

Recent Findings

Data suggests that microRNAs may be used to detect allograft rejection in cardiac transplantation and may predict the degree of myocardial recovery in patients with a left ventricular assist device or treated with beta-blocker therapy. Given their role in regulating cellular function, microRNAs are an intriguing target for oligonucleotide therapeutics, designed to mimic or antagonize (antagomir) their biological effects.

Summary

We review the current state of microRNAs as biomarkers of heart failure and associated conditions, the mechanisms by which microRNAs control cellular function, and how specific microRNAs may be targeted with novel therapeutics designed to treat heart failure.

Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science. 2001;291(5507):1304–51. https://doi.org/10.1126/science.1058040.PubMedCrossRef

Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921. https://doi.org/10.1038/35057062.PubMedCrossRef

Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.PubMedCrossRef

Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294(5543):853–8. https://doi.org/10.1126/science.1064921.PubMedCrossRef

Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 2001;294(5543):858–62. https://doi.org/10.1126/science.1065062.PubMedCrossRef

Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001;294(5543):862–4. https://doi.org/10.1126/science.1065329.PubMedCrossRef

Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic acids research. 2014;42(Database issue):D68–73. https://doi.org/10.1093/nar/gkt1181.PubMedCrossRef

•• Leptidis S, El Azzouzi H, Lok SI, de Weger R, Olieslagers S, Kisters N, et al. A deep sequencing approach to uncover the miRNOME in the human heart. PloS one. 2013;8(2):e57800. https://doi.org/10.1371/journal.pone.0057800. Next-generation sequencing of myocardial tissue identified novel microRNA species that are previously undescribed and are differentially regulated based on the etiology of heart failure. PubMedPubMedCentralCrossRef

Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, et al. MicroRNA-133 controls cardiac hypertrophy. Nature medicine. 2007;13(5):613–8. https://doi.org/10.1038/nm1582.PubMedCrossRef

10.

van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(48):18255–60. https://doi.org/10.1073/pnas.0608791103.PubMedPubMedCentralCrossRef

11.

Matkovich SJ, Hu Y, Eschenbacher WH, Dorn LE, Dorn GW 2nd. Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy. Circulation research. 2012;111(5):521–31. https://doi.org/10.1161/CIRCRESAHA.112.265736.

12.

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456(7224):980–4. https://doi.org/10.1038/nature07511.PubMedCrossRef

13.

Nagpal V, Rai R, Place AT, Murphy SB, Verma SK, Ghosh AK, et al. MiR-125b is critical for fibroblast-to-myofibroblast transition and cardiac fibrosis. Circulation. 2016;133(3):291–301. https://doi.org/10.1161/CIRCULATIONAHA.115.018174.PubMed

14.

Wang WC, Juan AH, Panebra A, Liggett SB. MicroRNA let-7 establishes expression of beta2-adrenergic receptors and dynamically down-regulates agonist-promoted down-regulation. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(15):6246–51. https://doi.org/10.1073/pnas.1101439108.PubMedPubMedCentralCrossRef

15.

Kim IM, Wang Y, Park KM, Tang Y, Teoh JP, Vinson J, et al. Beta-arrestin1-biased beta1-adrenergic receptor signaling regulates microRNA processing. Circulation research. 2014;114(5):833–44. https://doi.org/10.1161/CIRCRESAHA.114.302766.PubMedCrossRef

16.

Kumarswamy R, Lyon AR, Volkmann I, Mills AM, Bretthauer J, Pahuja A, et al. SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. Eur Heart J. 2012;33(9):1067–75. https://doi.org/10.1093/eurheartj/ehs043.PubMedPubMedCentralCrossRef

17.

Wahlquist C, Jeong D, Rojas-Munoz A, Kho C, Lee A, Mitsuyama S, et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature. 2014;508(7497):531–5. https://doi.org/10.1038/nature13073.PubMedPubMedCentralCrossRef

18.

Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 2007;116(3):258–67. https://doi.org/10.1161/CIRCULATIONAHA.107.687947.PubMedCrossRef

19.

Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: functional correlates. Journal of molecular and cellular cardiology. 2008;45(2):185–92. https://doi.org/10.1016/j.yjmcc.2008.04.014.PubMedPubMedCentralCrossRef

20.

Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circulation Cardiovascular genetics. 2010;3(6):499–506. https://doi.org/10.1161/CIRCGENETICS.110.957415.PubMedCrossRef

21.

Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al. MiR423-5p as a circulating biomarker for heart failure. Circulation research. 2010;106(6):1035–9. https://doi.org/10.1161/CIRCRESAHA.110.218297.PubMedCrossRef

22.

Waldenstrom A, Genneback N, Hellman U, Ronquist G. Cardiomyocyte microvesicles contain DNA/RNA and convey biological messages to target cells. PloS one. 2012;7(4):e34653. https://doi.org/10.1371/journal.pone.0034653.PubMedPubMedCentralCrossRef

23.

Ibanez-Ventoso C, Vora M, Driscoll M. Sequence relationships among C. elegans, D. melanogaster and human microRNAs highlight the extensive conservation of microRNAs in biology. PloS one. 2008;3(7):e2818. https://doi.org/10.1371/journal.pone.0002818.PubMedPubMedCentralCrossRef

24.

Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 2002;21(17):4663–70.PubMedPubMedCentralCrossRef

25.

Gurtan AM, Sharp PA. The role of miRNAs in regulating gene expression networks. Journal of molecular biology. 2013;425(19):3582–600. https://doi.org/10.1016/j.jmb.2013.03.007.PubMedPubMedCentralCrossRef

26.

Chiang HR, Schoenfeld LW, Ruby JG, Auyeung VC, Spies N, Baek D, et al. Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. Genes & development. 2010;24(10):992–1009. https://doi.org/10.1101/gad.1884710.CrossRef

27.

Neilsen CT, Goodall GJ, Bracken CP. IsomiRs—the overlooked repertoire in the dynamic microRNAome. Trends in genetics: TIG. 2012;28(11):544–9. https://doi.org/10.1016/j.tig.2012.07.005.PubMedCrossRef

28.

Port JD, Sucharov C. Role of microRNAs in cardiovascular disease: therapeutic challenges and potentials. Journal of cardiovascular pharmacology. 2010;56(5):444–53. https://doi.org/10.1097/FJC.0b013e3181f605b6.PubMedCrossRef

29.

Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circulation research. 2012;110(3):483–95. https://doi.org/10.1161/CIRCRESAHA.111.247452.PubMedCrossRef

30.

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006. https://doi.org/10.1038/cr.2008.282.PubMedCrossRef

31.

Felker GM, Ahmad T, Anstrom KJ, Adams KF, Cooper LS, Ezekowitz JA, et al. Rationale and design of the GUIDE-IT study: guiding evidence based therapy using biomarker intensified treatment in heart failure. JACC Heart failure. 2014;2(5):457–65. https://doi.org/10.1016/j.jchf.2014.05.007.PubMedPubMedCentralCrossRef

32.

Bikdeli B, Punnanithinont N, Akram Y, Lee I, Desai NR, Ross JS et al. Two decades of cardiovascular trials with primary surrogate endpoints: 1990-2011. J Am Heart Assoc. 2017;6(3). https://doi.org/10.1161/JAHA.116.005285.

33.

Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail. 2012;14(2):147–54. https://doi.org/10.1093/eurjhf/hfr155.PubMedCrossRef

34.

Seronde MF, Vausort M, Gayat E, Goretti E, Ng LL, Squire IB, et al. Circulating microRNAs and outcome in patients with acute heart failure. PloS one. 2015;10(11):e0142237. https://doi.org/10.1371/journal.pone.0142237.PubMedPubMedCentralCrossRef

35.

Xiao J, Gao R, Bei Y, Zhou Q, Zhou Y, Zhang H, et al. Circulating miR-30d predicts survival in patients with acute heart failure. Cell Physiol Biochem. 2017;41(3):865–74. https://doi.org/10.1159/000459899.PubMedPubMedCentralCrossRef

36.

Devaux B, Scholz D, Hirche A, Klovekorn WP, Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J. 1997;18(3):470–9.PubMedCrossRef

37.

Vogel B, Keller A, Frese KS, Leidinger P, Sedaghat-Hamedani F, Kayvanpour E, et al. Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure. Eur Heart J. 2013;34(36):2812–22. https://doi.org/10.1093/eurheartj/eht256.PubMedCrossRef

38.

Endo K, Naito Y, Ji X, Nakanishi M, Noguchi T, Goto Y, et al. MicroRNA 210 as a biomarker for congestive heart failure. Biol Pharm Bull. 2013;36(1):48–54.PubMedCrossRef

39.

Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 2012;5(3):492–7. https://doi.org/10.1158/1940-6207.CAPR-11-0370.PubMedCrossRef

40.

De Rosa S, Fichtlscherer S, Lehmann R, Assmus B, Dimmeler S, Zeiher AM. Transcoronary concentration gradients of circulating microRNAs. Circulation. 2011;124(18):1936–44. https://doi.org/10.1161/CIRCULATIONAHA.111.037572.PubMedCrossRef

41.

Boeckel JN, Reis SM, Leistner D, Thome CE, Zeiher AM, Fichtlscherer S, et al. From heart to toe: heart’s contribution on peripheral microRNA levels. International journal of cardiology. 2014;172(3):616–7. https://doi.org/10.1016/j.ijcard.2014.01.082.PubMedCrossRef

42.

Goldraich LA, Martinelli NC, Matte U, Cohen C, Andrades M, Pimentel M, et al. Transcoronary gradient of plasma microRNA 423-5p in heart failure: evidence of altered myocardial expression. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals. 2014;19(2):135–41. https://doi.org/10.3109/1354750X.2013.870605.CrossRef

43.

Marques FZ, Vizi D, Khammy O, Mariani JA, Kaye DM. The transcardiac gradient of cardio-microRNAs in the failing heart. Eur J Heart Fail. 2016;18(8):1000–8. https://doi.org/10.1002/ejhf.517.PubMedCrossRef

44.

Writing Group M, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–360. https://doi.org/10.1161/CIR.0000000000000350.CrossRef

45.

Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic heart failure in the community. Jama. 2006;296(18):2209–16. https://doi.org/10.1001/jama.296.18.2209.PubMedCrossRef

46.

Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–9. https://doi.org/10.1056/NEJMoa052256.PubMedCrossRef

47.

Ellis KL, Cameron VA, Troughton RW, Frampton CM, Ellmers LJ, Richards AM. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail. 2013;15(10):1138–47. https://doi.org/10.1093/eurjhf/hft078.PubMedCrossRef

48.

Wong LL, Armugam A, Sepramaniam S, Karolina DS, Lim KY, Lim JY, et al. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail. 2015;17(4):393–404. https://doi.org/10.1002/ejhf.223.PubMedCrossRef

49.

Watson CJ, Gupta SK, O'Connell E, Thum S, Glezeva N, Fendrich J, et al. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail. 2015;17(4):405–15. https://doi.org/10.1002/ejhf.244.PubMedPubMedCentralCrossRef

50.

Mehra MR, Parameshwar J. Gene expression profiling and cardiac allograft rejection monitoring: is IMAGE just a mirage? The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2010;29(6):599–602. https://doi.org/10.1016/j.healun.2010.04.010.CrossRef

51.

Kirklin JK, Naftel DC, Bourge RC, White-Williams C, Caulfield JB, Tarkka MR, et al. Rejection after cardiac transplantation. A time-related risk factor analysis. Circulation. 1992;86(5 Suppl):II236–41.PubMed

52.

Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, Cappola TP, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med. 2010;362(20):1890–900. https://doi.org/10.1056/NEJMoa0912965.PubMedCrossRef

53.

Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report—2016; focus theme: primary diagnostic indications for transplant. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2016;35(10):1158–69. https://doi.org/10.1016/j.healun.2016.08.017.CrossRef

54.

Wei L, Wang M, Qu X, Mah A, Xiong X, Harris AG, et al. Differential expression of microRNAs during allograft rejection. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012;12(5):1113–23. https://doi.org/10.1111/j.1600-6143.2011.03958.x.CrossRef

55.

Wei L, Kaul V, Qu X, Xiong X, Lau AH, Iwai N, et al. Absence of miR-182 augments cardiac allograft survival. Transplantation. 2017;101(3):524–30. https://doi.org/10.1097/TP.0000000000001345.PubMedCrossRef

56.

Van Aelst LN, Summer G, Li S, Gupta SK, Heggermont W, De Vusser K, et al. RNA profiling in human and murine transplanted hearts: identification and validation of therapeutic targets for acute cardiac and renal allograft rejection. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2016;16(1):99–110. https://doi.org/10.1111/ajt.13421.CrossRef

57.

Gupta SK, Itagaki R, Zheng X, Batkai S, Thum S, Ahmad F, et al. miR-21 promotes fibrosis in an acute cardiac allograft transplantation model. Cardiovascular research. 2016;110(2):215–26. https://doi.org/10.1093/cvr/cvw030.PubMedCrossRef

58.

Sukma Dewi I, Celik S, Karlsson A, Hollander Z, Lam K, McManus JW, et al. Exosomal miR-142-3p is increased during cardiac allograft rejection and augments vascular permeability through down-regulation of endothelial RAB11FIP2 expression. Cardiovascular research. 2017;113(5):440–52. https://doi.org/10.1093/cvr/cvw244.PubMed

59.

Sukma Dewi I, Torngren K, Gidlof O, Kornhall B, Ohman J. Altered serum miRNA profiles during acute rejection after heart transplantation: potential for non-invasive allograft surveillance. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2013;32(4):463–6. https://doi.org/10.1016/j.healun.2012.12.007.CrossRef

60.

•• Duong Van Huyen JP, Tible M, Gay A, Guillemain R, Aubert O, Varnous S, et al. MicroRNAs as non-invasive biomarkers of heart transplant rejection. Eur Heart J. 2014;35(45):3194–202. https://doi.org/10.1093/eurheartj/ehu346. The group investigated a panel of previously reported microRNAs implicated in rejection in myocardial tissue and blood samples of patients with and without cardiac allograft rejection and the two main subtypes: cellular and antibody-mediated. They identified a panel of miRs with high sensitivity and specificity for diagnosing rejection and its subtypes in the circulation. PubMedCrossRef

61.

Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012;41(6):1897–912. https://doi.org/10.3892/ijo.2012.1647.PubMedCrossRef

62.

Neal CS, Michael MZ, Pimlott LK, Yong TY, Li JY, Gleadle JM. Circulating microRNA expression is reduced in chronic kidney disease. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2011;26(11):3794–802. https://doi.org/10.1093/ndt/gfr485.CrossRef

63.

Singh N, Heggermont W, Fieuws S, Vanhaecke J, Van Cleemput J, De Geest B. Endothelium-enriched microRNAs as diagnostic biomarkers for cardiac allograft vasculopathy. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2015;34(11):1376–84. https://doi.org/10.1016/j.healun.2015.06.008.CrossRef

64.

Neumann A, Napp LC, Kleeberger JA, Benecke N, Pfanne A, Haverich A, et al. MicroRNA 628-5p as a novel biomarker for cardiac allograft vasculopathy. Transplantation. 2016; https://doi.org/10.1097/TP.0000000000001477.

65.

Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Seventh INTERMACS annual report: 15,000 patients and counting. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2015;34(12):1495–504. https://doi.org/10.1016/j.healun.2015.10.003.CrossRef

66.

Birks EJ, George RS, Hedger M, Bahrami T, Wilton P, Bowles CT, et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation. 2011;123(4):381–90. https://doi.org/10.1161/CIRCULATIONAHA.109.933960.PubMedCrossRef

67.

Hellawell JL, Margulies KB. Myocardial reverse remodeling. Cardiovascular therapeutics. 2012;30(3):172–81. https://doi.org/10.1111/j.1755-5922.2010.00247.x.PubMedCrossRef

68.

Drakos SG, Pagani FD, Lundberg MS, Baldwin JT. Advancing the science of myocardial recovery with mechanical circulatory support: a Working Group of the National, Heart, Lung and Blood Institute. J Card Fail. 2017;23(5):416–21. https://doi.org/10.1016/j.cardfail.2017.04.005.PubMedCrossRef

69.

Akat KM, Moore-McGriff D, Morozov P, Brown M, Gogakos T, Correa Da Rosa J, et al. Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(30):11151–6. https://doi.org/10.1073/pnas.1401724111.PubMedPubMedCentralCrossRef

70.

Schipper ME, van Kuik J, de Jonge N, Dullens HF, de Weger RA. Changes in regulatory microRNA expression in myocardium of heart failure patients on left ventricular assist device support. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2008;27(12):1282–5. https://doi.org/10.1016/j.healun.2008.09.005.CrossRef

71.

Yang KC, Yamada KA, Patel AY, Topkara VK, George I, Cheema FH, et al. Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support. Circulation. 2014;129(9):1009–21. https://doi.org/10.1161/CIRCULATIONAHA.113.003863.PubMedPubMedCentralCrossRef

72.

Lok SI, van Mil A, Bovenschen N, van der Weide P, van Kuik J, van Wichen D, et al. Post-transcriptional regulation of alpha-1-antichymotrypsin by microRNA-137 in chronic heart failure and mechanical support. Circulation Heart failure. 2013;6(4):853–61. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000255.PubMedCrossRef

73.

Ramani R, Vela D, Segura A, McNamara D, Lemster B, Samarendra V, et al. A micro-ribonucleic acid signature associated with recovery from assist device support in 2 groups of patients with severe heart failure. J Am Coll Cardiol. 2011;58(22):2270–8. https://doi.org/10.1016/j.jacc.2011.08.041.PubMedPubMedCentralCrossRef

74.

Lok SI, de Jonge N, van Kuik J, van Geffen AJ, Huibers MM, van der Weide P, et al. MicroRNA expression in myocardial tissue and plasma of patients with end-stage heart failure during LVAD support: comparison of continuous and pulsatile devices. PloS one. 2015;10(10):e0136404. https://doi.org/10.1371/journal.pone.0136404.PubMedPubMedCentralCrossRef

75.

Sucharov CC, Kao DP, Port JD, Karimpour-Fard A, Quaife RA, Minobe W, et al. Myocardial microRNAs associated with reverse remodeling in human heart failure. JCI Insight. 2017;2(2):e89169. https://doi.org/10.1172/jci.insight.89169.PubMedPubMedCentralCrossRef

76.

Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A, Eschenbacher WH, et al. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation. 2009;119(9):1263–71. https://doi.org/10.1161/CIRCULATIONAHA.108.813576.PubMedPubMedCentralCrossRef

77.

Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Hadfield J, et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. Rna. 2010;16(5):991–1006. https://doi.org/10.1261/rna.1947110.PubMedPubMedCentralCrossRef

78.

Morley-Smith AC, Mills A, Jacobs S, Meyns B, Rega F, Simon AR, et al. Circulating microRNAs for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device. Eur J Heart Fail. 2014;16(8):871–9. https://doi.org/10.1002/ejhf.116.PubMedPubMedCentralCrossRef

79.

Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation. 1996;94(9):2285–96.PubMedCrossRef

80.

Barsheshet A, Goldenberg I, Moss AJ, Eldar M, Huang DT, McNitt S, et al. Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. Eur Heart J. 2011;32(13):1622–30. https://doi.org/10.1093/eurheartj/ehq407.PubMedCrossRef

81.

Marfella R, Di Filippo C, Potenza N, Sardu C, Rizzo MR, Siniscalchi M, et al. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. Eur J Heart Fail. 2013;15(11):1277–88. https://doi.org/10.1093/eurjhf/hft088.PubMedCrossRef

82.

•• Melman YF, Shah R, Danielson K, Xiao J, Simonson B, Barth A, et al. Circulating MicroRNA-30d is associated with response to cardiac resynchronization therapy in heart failure and regulates cardiomyocyte apoptosis: a translational pilot study. Circulation. 2015;131(25):2202–16. https://doi.org/10.1161/CIRCULATIONAHA.114.013220. Translational study that evaluated response to CRT and identified miR-30d as a potential marker of CRT response. Using animal models identified that miR-30d is secreted in response to wall stress and protects cardiac myocytes from apoptosis. PubMedPubMedCentralCrossRef

83.

Kao DP, Lowes BD, Gilbert EM, Minobe W, Epperson LE, Meyer LK, et al. Therapeutic molecular phenotype of beta-blocker-associated reverse-remodeling in nonischemic dilated cardiomyopathy. Circulation Cardiovascular genetics. 2015;8(2):270–83. https://doi.org/10.1161/CIRCGENETICS.114.000767.PubMedCrossRef

84.

Miyamoto SD, Karimpour-Fard A, Peterson V, Auerbach SR, Stenmark KR, Stauffer BL, et al. Circulating microRNA as a biomarker for recovery in pediatric dilated cardiomyopathy. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2015;34(5):724–33. https://doi.org/10.1016/j.healun.2015.01.979.CrossRef

85.

Stein RAA. Forgoing the comforts of small molecules and antibodies, some drug developers are setting their sights on RNAi-based therapeutics. Genet Eng Biotechnol News. 2017;37(11).

86.

Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiological reviews. 2016;96(4):1297–325. https://doi.org/10.1152/physrev.00041.2015.PubMedCrossRef

87.

Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nature biotechnology. 2017;35(3):238–48. https://doi.org/10.1038/nbt.3765.PubMedPubMedCentralCrossRef

88.

Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–22. https://doi.org/10.1038/nrd.2016.246.PubMedCrossRef

89.

Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368(18):1685–94. https://doi.org/10.1056/NEJMoa1209026.PubMedCrossRef

90.

Regulus announces continuation of RG-101 Clinical Hold. Online. 2017. http://www.prnewswire.com/news-releases/regulus-announces-continuation-of-rg-101-clinical-hold-300398301.html. Accessed 7 August 2017.

91.

Mirna Therapeutics halts Phase 1 Clinical Study of MRX34. Online. 2016. http://investor.mirnarx.com/releasedetail.cfm?releaseid=990204. Accessed 7 August 2017.

92.

van Rooij E, Marshall WS, Olson EN. Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circulation research. 2008;103(9):919–28. https://doi.org/10.1161/CIRCRESAHA.108.183426.PubMedPubMedCentralCrossRef

93.

Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation. 2011;124(14):1537–47. https://doi.org/10.1161/CIRCULATIONAHA.111.030932.PubMedPubMedCentralCrossRef

94.

Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, Condorelli G, et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circulation research. 2010;106(1):166–75. https://doi.org/10.1161/CIRCRESAHA.109.202176.PubMedCrossRef

95.

Keller T, Boeckel JN, Gross S, Klotsche J, Palapies L, Leistner D, et al. Improved risk stratification in prevention by use of a panel of selected circulating microRNAs. Sci Rep. 2017;7(1):4511. https://doi.org/10.1038/s41598-017-04040-w.PubMedPubMedCentralCrossRef

96.

Chen Z, Li C, Xu Y, Li Y, Yang H, Rao L. Circulating level of miR-378 predicts left ventricular hypertrophy in patients with aortic stenosis. PloS one. 2014;9(8):e105702. https://doi.org/10.1371/journal.pone.0105702.PubMedPubMedCentralCrossRef

97.

Carrer M, Liu N, Grueter CE, Williams AH, Frisard MI, Hulver MW, et al. Control of mitochondrial metabolism and systemic energy homeostasis by microRNAs 378 and 378*. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(38):15330–5. https://doi.org/10.1073/pnas.1207605109.PubMedPubMedCentralCrossRef

98.

Nagalingam RS, Sundaresan NR, Gupta MP, Geenen DL, Solaro RJ, Gupta M. A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling. The Journal of biological chemistry. 2013;288(16):11216–32. https://doi.org/10.1074/jbc.M112.442384.PubMedPubMedCentralCrossRef

99.

Ganesan J, Ramanujam D, Sassi Y, Ahles A, Jentzsch C, Werfel S, et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation. 2013;127(21):2097–106. https://doi.org/10.1161/CIRCULATIONAHA.112.000882.PubMedCrossRef

100.

Nagalingam RS, Sundaresan NR, Noor M, Gupta MP, Solaro RJ, Gupta M. Deficiency of cardiomyocyte-specific microRNA-378 contributes to the development of cardiac fibrosis involving a transforming growth factor beta (TGFbeta1)-dependent paracrine mechanism. The Journal of biological chemistry. 2014;289(39):27199–214. https://doi.org/10.1074/jbc.M114.580977.PubMedPubMedCentralCrossRef

Titel: MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential
verfasst von: Palak Shah
Michael R. Bristow
J. David Port
Publikationsdatum: 22.09.2017
Verlag: Springer US
Erschienen in: Current Heart Failure Reports / Ausgabe 6/2017
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-017-0362-8

Neu im Fachgebiet Kardiologie

23.04.2024 | Ablationstherapie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Clinical Application of Genetic Testing in Heart Failure

Defining Ambulatory Advanced Heart Failure: MedaMACS and Beyond

Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure

Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment

Prevention and Treatment of Thrombotic and Hemorrhagic Complications in Patients Supported by Continuous-Flow Left Ventricular Assist Devices

Glycosylated Chromogranin A: Potential Role in the Pathogenesis of Heart Failure

Neu im Fachgebiet Kardiologie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Kardiologie